文献速递造血干细胞移植与细胞治疗血栓与止血

去纤苷治疗造血干细胞移植后肝静脉闭塞病/窦状隙阻塞综合征的真实世界管理经验

Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant.
PubMed 文献 · Blood Adv · 2022-01-01

该单中心回顾性研究纳入28例符合EBMT标准的HSCT后VOD/SOS患者,评估商业可及去纤苷的疗效与安全性。VOD/SOS中位起病时间为25天,71%患者在诊断当日启动去纤苷,完全缓解率75%,全部HSCT患者第100天生存率64%,极重度VOD/SOS患者为53%。治疗相关不良事件以轻度为主,严重出血事件发生率7%。

要点

  • 去纤苷治疗HSCT后VOD/SOS完全缓解率达75%,第100天生存率64%。
  • 极重度VOD/SOS患者第100天生存率为53%,清髓与非清髓移植后疗效相似。
  • 早期诊断、及时启动去纤苷并减少给药中断可能是治疗成功的关键。

核心结论

  • 去纤苷治疗HSCT后VOD/SOS可获得较高的完全缓解率和第100天生存率,且安全性可控。

研究设计与样本

  • 单中心回顾性研究,基于EBMT标准于2016年3月至2019年6月识别28例HSCT后VOD/SOS患者,评估商业可及去纤苷的治疗经验。

主要发现

  • VOD/SOS中位起病时间为25天(范围8-69天),71%患者在诊断当日启动去纤苷。
  • 75%患者VOD/SOS完全缓解;全部HSCT患者第100天生存率64%,极重度VOD/SOS患者为53%。
  • 清髓性与减低强度化疗HSCT后VOD/SOS患者的缓解率和生存率相似。
  • 治疗相关不良事件轻微,包括血尿(43%)、鼻出血(18%)和低血压(11%)。
  • 严重出血不良事件发生于2例患者(肺出血和上消化道出血;7%),均处于进展性VOD/SOS背景。

关键数值与推荐

  • VOD/SOS诊断依据EBMT标准。
  • 完全缓解率75%,第100天生存率全部患者64%、极重度患者53%。
  • 治疗相关不良事件:血尿43%、鼻出血18%、低血压11%;严重出血事件7%。

临床怎么用

  • 对HSCT后疑似VOD/SOS应尽早按EBMT标准诊断并启动去纤苷,尽量减少给药中断。
  • 治疗期间需监测血尿、鼻出血、低血压等不良事件,尤其进展性VOD/SOS患者警惕严重出血。

局限性

  • 单中心回顾性研究,样本量28例,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatic veno-occlusive disease or sinusoidal obstructive syndrome (VOD/SOS) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT). Defibrotide is the only medication approved by the US Food and Drug Administration for the management of severe VOD/SOS after HSCT. We report our center's experience with commercially available defibrotide as treatment of patients with VOD/SOS. We retrospectively identified 28 cases of VOD/SOS, based on the European Society for Blood and Marrow Transplantation criteria, from March 2016 through June 2019. The median day of VOD/SOS onset was 25 days (range, 8-69 days), and defibrotide was initiated on day of diagnosis in 71% of patients. Complete resolution of VOD/SOS occurred in 75% of patients. Day 100 survival was 64% for all HSCT patients and 53% for those with very severe VOD/SOS. Response rates and survival were similar in patients with VOD/SOS after myeloablative or reduced-intensity chemotherapy HSCT. Therapy-related adverse events were mild and included hematuria (43%), epistaxis (18%), and hypotension (11%). Severe hemorrhagic adverse events occurred in 2 patients (pulmonary hemorrhage and upper gastrointestinal hemorrhage; 7%) and both in the setting of progressive VOD/SOS. Early diagnosis, prompt initiation of defibrotide, and minimization of dosing interruptions may be key to successful treatment of VOD/SOS.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Nauffal M, Kim HT, Richardson PG, et al. Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant. Blood Adv. 2022. PMID: 34666352. doi:10.1182/bloodadvances.2021005410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。